Latest Breaking News On - Pieris pharmaceuticals inc - Page 41 : comparemela.com

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

United statesMaria kelmanPieris pharmaceuticalsPieris pharmaceuticals incJefferies healthcare conferenceRelations contactUnited states wire group

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesMaria kelmanPieris pharmaceuticalsPieris pharmaceuticals incJefferies healthcare conferenceRelations contact

$10 47 Million in Sales Expected for Pieris Pharmaceuticals, Inc (NASDAQ:PIRS) This Quarter

Wall Street brokerages predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) will announce sales of $10.47 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings, with estimates ranging from $3.24 million to $17.70 million. Pieris Pharmaceuticals posted sales of $3.29 million in the same […]

Pieris pharmaceuticals company profile get ratingCetera advisorsMirabella financial servicesZacks investment researchPieris pharmaceuticalsOppenheimer coTopco ltdRoyal bankPieris pharmaceuticals incWall streetGet ratingZacks investmentPieris pharmaceuticalInvestment researchFinancial servicesPharmaceuticals company profile

Analysts Anticipate Pieris Pharmaceuticals, Inc (NASDAQ:PIRS) to Post -$0 11 EPS

Equities research analysts expect that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) will announce ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.02). Pieris Pharmaceuticals posted […]

Great point partnersPieris pharmaceuticals company profile get ratingMirabella financial servicesZacks investment researchPieris pharmaceuticalsPieris pharmaceuticals incGet ratingPieris pharmaceuticalInvestment researchFinancial servicesStreet groupPoint partnersStreet corpPharmaceuticals company profileNasdaq pirs

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals To Present at H C Wainwright Global Investment Conference

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesMaria kelmanPieris pharmaceuticalsPieris pharmaceuticals incGlobal investment conferenceRelations contact